LRMR
Larimar Therapeutics Inc.
$3.56
+$0.19(+5.64%)
39
Overall
60
Value
18
Tech
--
Quality
Market Cap
$292.72M
Volume
1.15M
52W Range
$1.61 - $6.91
Target Price
$16.70
Company Overview
| Mkt Cap | $292.72M | Price | $3.56 |
| Volume | 1.15M | Change | +5.64% |
| P/E Ratio | -3.6 | Open | $3.34 |
| Revenue | -- | Prev Close | $3.37 |
| Net Income | $-80.6M | 52W Range | $1.61 - $6.91 |
| Div Yield | N/A | Target | $16.70 |
| Overall | 39 | Value | 60 |
| Quality | -- | Technical | 18 |
No chart data available
About Larimar Therapeutics Inc.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Latest News
Larimar Therapeutics Shows Promise in Friedreich’s Ataxia Treatment
TipRanks Auto-Generated Newsdesk•17 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | LRMR | $3.56 | +5.6% | 1.15M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Larimar Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW